Last reviewed · How we verify
Interferon beta-1b and Tacrolimus — Competitive Intelligence Brief
phase 2
Small molecule
Live · refreshed every 30 min
Target snapshot
Interferon beta-1b and Tacrolimus (Interferon beta-1b and Tacrolimus) — Clinique de sclérose en plaques et neuromusculaire de l'Outaouais.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Interferon beta-1b and Tacrolimus TARGET | Interferon beta-1b and Tacrolimus | Clinique de sclérose en plaques et neuromusculaire de l'Outaouais | phase 2 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Interferon beta-1b and Tacrolimus CI watch — RSS
- Interferon beta-1b and Tacrolimus CI watch — Atom
- Interferon beta-1b and Tacrolimus CI watch — JSON
- Interferon beta-1b and Tacrolimus alone — RSS
Cite this brief
Drug Landscape (2026). Interferon beta-1b and Tacrolimus — Competitive Intelligence Brief. https://druglandscape.com/ci/interferon-beta-1b-and-tacrolimus. Accessed 2026-05-17.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab